Gita Vita Soraya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Gita Vita Soraya has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Zulvikar Syambani Ulhaq
Research Center for Pre-Clinical and Clinical Medicine, National Research and Innovation Agency Republic of Indonesia, Cibinong 16911, Indonesia
12 shared publications Marhaen Hardjo
Department of Biomedicine Graduate School Hasanuddin University Makassar Indonesia
5 shared publicationsGursharan Chana
MX3 Diagnostics Inc. Melbourne Victoria Australia
4 shared publicationsRosdiana Natzir
Department of Biomedicine Graduate School Hasanuddin University Makassar Indonesia
4 shared publicationsEfstratios Skafidas
MX3 Diagnostics Inc. Melbourne Victoria Australia
3 shared publications- Efstratios Skafidas
Department of Electrical and Electronic Engineering Faculty of Engineering and Information Technology The University of Melbourne Parkville VIC 3010 Australia
3 shared publications
Latest Publications
- 23 September 2026
- Published by Bentham Science Publishers Ltd. in Current Bioactive Compounds
- Vol. 22, 1-20
Multi-target Mechanisms of Moringa oleifera Stem Bark Compounds against Luminal A Breast Cancer: Integrative In silico and In vitro Analyses
Introduction: Luminal A Breast Cancer (LABC) remains a pressing global health concern. Natural products have been widely explored as alternative anticancer agents. Moringa oleifera L. has demonstrated anticancer potential; however, studies on its stem bark are limited. Methods: M. oleifera Stem Bark (MO extract was analyzed by GC-MS, and identified compounds were subjected to in silico evaluation using ADMET, PASS, and SwissTargetPrediction. Network pharmacology and UALCAN (TCGA-BRCA) were utilized to validate the expression of hub genes. Cytotoxicity against MCF-7 cells was assessed using the MTT assay, and the IC₂⁽ was determined via four-parameter logistic (4PL) regression. Results: Twenty bioactive main compounds were discovered, including steroids (D-Homoestra- 1,3,5(10),8(14)-tetraen-17-one), terpenoids (1H-3a,6-Methanoazulene-3-carboxylic acid methyl ester), and retinoids (9-cis-Retinal). Eight key targets (STAT3, HSP90AA1, BCL2, GAPDH, PPARG, PTGS2, EGFR, and IL1B) were enriched in key oncogenic pathways involved in enhanced proliferation, reduced apoptosis, active metabolism, and lower inflammatory and differentiation signaling. The extract inhibited MCF-7 viability from 19.8% (3.9 μg/mL) to 83.4% (250 μg/mL), with an IC50 of 42.8 μg/mL (R² = 0.9805). Morphological changes suggestive of apoptosis are characterized by cell shrinkage and detachment. Discussion: The multi-target profile of MOSB points to coordinated modulation of proliferative, anti-apoptotic, metabolic, and inflammatory pathways in LABC cells. The observed cytotoxicity (IC50: 42.8 μg/mL) and apoptotic morphology support the network pharmacology predictions, indicating combined effects of the bioactive compounds. Conclusions: MOSB ethanolic extract exhibits antiproliferative activity against LABC and may involve multi-target modulation, supporting its potential for further in vivo and mechanistic validation.
- 23 September 2026
- Published by Bentham Science Publishers Ltd. in Current Bioactive Compounds
- Vol. 22, 1-20
Multi-target Mechanisms of Moringa oleifera Stem Bark Compounds against Luminal A Breast Cancer: Integrative In silico and In vitro Analyses
Introduction: Luminal A Breast Cancer (LABC) remains a pressing global health concern. Natural products have been widely explored as alternative anticancer agents. Moringa oleifera L. has demonstrated anticancer potential; however, studies on its stem bark are limited. Methods: M. oleifera Stem Bark (MO extract was analyzed by GC-MS, and identified compounds were subjected to in silico evaluation using ADMET, PASS, and SwissTargetPrediction. Network pharmacology and UALCAN (TCGA-BRCA) were utilized to validate the expression of hub genes. Cytotoxicity against MCF-7 cells was assessed using the MTT assay, and the IC₂⁽ was determined via four-parameter logistic (4PL) regression. Results: Twenty bioactive main compounds were discovered, including steroids (D-Homoestra- 1,3,5(10),8(14)-tetraen-17-one), terpenoids (1H-3a,6-Methanoazulene-3-carboxylic acid methyl ester), and retinoids (9-cis-Retinal). Eight key targets (STAT3, HSP90AA1, BCL2, GAPDH, PPARG, PTGS2, EGFR, and IL1B) were enriched in key oncogenic pathways involved in enhanced proliferation, reduced apoptosis, active metabolism, and lower inflammatory and differentiation signaling. The extract inhibited MCF-7 viability from 19.8% (3.9 μg/mL) to 83.4% (250 μg/mL), with an IC50 of 42.8 μg/mL (R² = 0.9805). Morphological changes suggestive of apoptosis are characterized by cell shrinkage and detachment. Discussion: The multi-target profile of MOSB points to coordinated modulation of proliferative, anti-apoptotic, metabolic, and inflammatory pathways in LABC cells. The observed cytotoxicity (IC50: 42.8 μg/mL) and apoptotic morphology support the network pharmacology predictions, indicating combined effects of the bioactive compounds. Conclusions: MOSB ethanolic extract exhibits antiproliferative activity against LABC and may involve multi-target modulation, supporting its potential for further in vivo and mechanistic validation.
- Open Access
- 4 June 2026
- Published by Taylor & Francis in Disability and Rehabilitation
- p. 1-13
National survey of stroke rehabilitation services in Indonesia
To describe stroke rehabilitation services in Indonesia. Cross-sectional online survey (June-August 2023) assessed sub-acute stroke rehabilitation service provision in Indonesia. Adapted from international examples, the survey explored service characteristics including staffing, session frequency, duration, and insurance coverage. A convenience sample of hospital and community health centre staff delivering rehabilitation was recruited through the Indonesian Angels Initiative and the Indonesian Physiotherapy Association. Eighty-one responses were received from 24/38 (63%) Indonesian provinces; 72 (89%) from hospitals and nine (11%) from community health centres. All respondents were physiotherapists. Most hospitals offered outpatient rehabilitation (82%); 93% of referrals were from acute neurology; 90% of hospital rehabilitation services reported patients were covered by national health insurance. All hospitals had physiotherapists; 83% (n = 60) had rehabilitation physicians, and one-third had occupational or speech therapists. Two-thirds provided rehabilitation 2-3 times/week for up to an hour/session, primarily focusing on strength and range of motion exercises. At community health centres, most patients were self-referred (67%), and were supported through a combination of health insurance and self-funded payments (67%). This study presents detailed cross-sectional data on Indonesian sub-acute stroke rehabilitation services, which are primarily provided by hospital-based outpatient services, with therapy provision below international clinical practice guideline recommendations.
- 4 June 2026
- Published by Taylor & Francis in Disability and Rehabilitation
- p. 1-13
Open AccessNational survey of stroke rehabilitation services in Indonesia
To describe stroke rehabilitation services in Indonesia. Cross-sectional online survey (June-August 2023) assessed sub-acute stroke rehabilitation service provision in Indonesia. Adapted from international examples, the survey explored service characteristics including staffing, session frequency, duration, and insurance coverage. A convenience sample of hospital and community health centre staff delivering rehabilitation was recruited through the Indonesian Angels Initiative and the Indonesian Physiotherapy Association. Eighty-one responses were received from 24/38 (63%) Indonesian provinces; 72 (89%) from hospitals and nine (11%) from community health centres. All respondents were physiotherapists. Most hospitals offered outpatient rehabilitation (82%); 93% of referrals were from acute neurology; 90% of hospital rehabilitation services reported patients were covered by national health insurance. All hospitals had physiotherapists; 83% (n = 60) had rehabilitation physicians, and one-third had occupational or speech therapists. Two-thirds provided rehabilitation 2-3 times/week for up to an hour/session, primarily focusing on strength and range of motion exercises. At community health centres, most patients were self-referred (67%), and were supported through a combination of health insurance and self-funded payments (67%). This study presents detailed cross-sectional data on Indonesian sub-acute stroke rehabilitation services, which are primarily provided by hospital-based outpatient services, with therapy provision below international clinical practice guideline recommendations.
- Open Access
- 17 October 2025
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 17, 1632480
Elucidating the role of APOE ε4 gene variants in the clinical manifestation of Parkinson's disease
Introduction: Parkinson's Disease (PD) is the most common movement disorder, and remains a major cause of mortality and morbidity worldwide. Studies have uncovered the potential role of the Apolipoprotein (APOE) gene in PD, although results have been conflicting. This study aimed to characterize the APOE ε4 status of Indonesian PD subjects and perform a meta-analysis to elucidate it's role in PD onset age, disease severity, and cognition.Methods: APOE ε4 genotyping was performed on PD patients and their respective healthy families. Clinical parameters were obtained from PD patients. Secondly, we conducted a meta-analysis on the role of APOE ε4, with studies collected until January 2025. Retrieved parameters include the number of PD APOE ε4 allele carriers and non-carriers, age of onset, disease severity, and mini-mental state examination (MMSE) scores.Results: Four of the 7 recruited subjects were APOE ε4 carriers, with 2 out of 3 PD subjects of APOE ε4 carrier status. In the meta-analysis, 14 included studies revealed a significantly younger age of onset in APOE ε4 carriers (SMD = −0.16, 95%CI −0.24 to −0.08, p = 0.0001) relative to non-carriers. Six included studies revealed no significant difference in the Hoehn and Yahr disease severity, and 4 included studies showed no significant difference in MMSE scores of carriers vs. non-carriers.Conclusion: The APOE ε4 allele is common in this preliminary study of 3 PD subjects. Our meta-analysis revealed a significantly earlier age-of-onset among APOE ε4 carriers relative to non-carriers, but no difference in disease severity and MMSE scores.
- 17 October 2025
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 17, 1632480
Open AccessElucidating the role of APOE ε4 gene variants in the clinical manifestation of Parkinson's disease
Introduction: Parkinson's Disease (PD) is the most common movement disorder, and remains a major cause of mortality and morbidity worldwide. Studies have uncovered the potential role of the Apolipoprotein (APOE) gene in PD, although results have been conflicting. This study aimed to characterize the APOE ε4 status of Indonesian PD subjects and perform a meta-analysis to elucidate it's role in PD onset age, disease severity, and cognition.Methods: APOE ε4 genotyping was performed on PD patients and their respective healthy families. Clinical parameters were obtained from PD patients. Secondly, we conducted a meta-analysis on the role of APOE ε4, with studies collected until January 2025. Retrieved parameters include the number of PD APOE ε4 allele carriers and non-carriers, age of onset, disease severity, and mini-mental state examination (MMSE) scores.Results: Four of the 7 recruited subjects were APOE ε4 carriers, with 2 out of 3 PD subjects of APOE ε4 carrier status. In the meta-analysis, 14 included studies revealed a significantly younger age of onset in APOE ε4 carriers (SMD = −0.16, 95%CI −0.24 to −0.08, p = 0.0001) relative to non-carriers. Six included studies revealed no significant difference in the Hoehn and Yahr disease severity, and 4 included studies showed no significant difference in MMSE scores of carriers vs. non-carriers.Conclusion: The APOE ε4 allele is common in this preliminary study of 3 PD subjects. Our meta-analysis revealed a significantly earlier age-of-onset among APOE ε4 carriers relative to non-carriers, but no difference in disease severity and MMSE scores.
- 25 January 2025
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Determinants of Stroke Following Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis
INPLASY202510106 Determinants of Stroke Following Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis Keywords: Acute Coronary Syndrom…
- 25 January 2025
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Determinants of Stroke Following Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis
INPLASY202510106 Determinants of Stroke Following Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis Keywords: Acute Coronary Syndrom…
- Open Access
- 1 November 2024
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. ume 20, 521-531
Non-Contrast MRI Sequences for Ischemic Stroke: A Concise Overview for Clinical Radiologists
Ischemic stroke is the second leading cause of mortality and morbidity worldwide. Due to the urgency of implementing immediate therapy, acute stroke necessitates prompt diagnosis. The current gold standards for vascular imaging in stroke include computed tomography angiography (CTA), digital subtraction angiography (DSA) and magnetic resonance angiography (MRA). However, the contrast agents used in these methods can be costly and pose risks for patients with renal impairment or allergies. The aim of this paper is to provide a comprehensive overview of current MRI techniques and sequences for evaluating ischemic stroke, emphasizing the importance of non-contrast options and their clinical implications for radiologists in the diagnosis and management of ischemic stroke. Standard MRI sequences—such as T1-weighted imaging (T1WI), T2-weighted imaging (T2WI), fluid-attenuated inversion recovery (FLAIR), diffusion-weighted imaging (DWI), DWI-FLAIR mismatch, and apparent diffusion coefficient (ADC)—are essential for determining infarct location, volume, and age. Additionally, incorporating susceptibility-weighted imaging (SWI) sequence aids in identifying signs of hemorrhagic transformation within the infarcted region. Advanced techniques like arterial spin labeling (ASL) can serve as a non-contrast alternative for mapping cerebral blood flow (CBF) and allowing for comparison between infarcted and healthy brain areas. Adding ASL to the routine sequence allows ASL-DWI mismatch analysis that is useful for quantifying salvageable tissue volume and facilitate timely recanalization, while time-of-flight (TOF) MRA and magnetic resonance venography (MRV) help assess venous thrombosis, stenosis, or arterial occlusions. Finally, MR spectroscopy can provide insights into critical brain metabolites, including N-acetylaspartate (NAA), and lactate (Lac) to determine patient prognosis. Current MRI technology provides a myriad of sequence options for the comprehensive evaluation of ischemic stroke without the need for contrast material. A thorough understanding of the advantages and limitations of each sequence is crucial for its optimal implementation in diagnosis and treatment.
- 1 November 2024
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. ume 20, 521-531
Open AccessNon-Contrast MRI Sequences for Ischemic Stroke: A Concise Overview for Clinical Radiologists
Ischemic stroke is the second leading cause of mortality and morbidity worldwide. Due to the urgency of implementing immediate therapy, acute stroke necessitates prompt diagnosis. The current gold standards for vascular imaging in stroke include computed tomography angiography (CTA), digital subtraction angiography (DSA) and magnetic resonance angiography (MRA). However, the contrast agents used in these methods can be costly and pose risks for patients with renal impairment or allergies. The aim of this paper is to provide a comprehensive overview of current MRI techniques and sequences for evaluating ischemic stroke, emphasizing the importance of non-contrast options and their clinical implications for radiologists in the diagnosis and management of ischemic stroke. Standard MRI sequences—such as T1-weighted imaging (T1WI), T2-weighted imaging (T2WI), fluid-attenuated inversion recovery (FLAIR), diffusion-weighted imaging (DWI), DWI-FLAIR mismatch, and apparent diffusion coefficient (ADC)—are essential for determining infarct location, volume, and age. Additionally, incorporating susceptibility-weighted imaging (SWI) sequence aids in identifying signs of hemorrhagic transformation within the infarcted region. Advanced techniques like arterial spin labeling (ASL) can serve as a non-contrast alternative for mapping cerebral blood flow (CBF) and allowing for comparison between infarcted and healthy brain areas. Adding ASL to the routine sequence allows ASL-DWI mismatch analysis that is useful for quantifying salvageable tissue volume and facilitate timely recanalization, while time-of-flight (TOF) MRA and magnetic resonance venography (MRV) help assess venous thrombosis, stenosis, or arterial occlusions. Finally, MR spectroscopy can provide insights into critical brain metabolites, including N-acetylaspartate (NAA), and lactate (Lac) to determine patient prognosis. Current MRI technology provides a myriad of sequence options for the comprehensive evaluation of ischemic stroke without the need for contrast material. A thorough understanding of the advantages and limitations of each sequence is crucial for its optimal implementation in diagnosis and treatment.
- Open Access
- 13 October 2024
- Published by Uniwersytet Warminsko-Mazurski in Polish Annals of Medicine
- Vol. 31 (2) , 1-5
Steroid response in a rare case of vertebrae butterfly with spinal cord compression caused by chronic subdural hematoma
Introduction: Spinal subdural hematoma (SSH) is a rare entity. Clinical symptoms include motor, sensory and/or autonomic dysfunction due to compression of the spinal cord. There is no standard consensus in the management of SSH. Here, we report a rare case of SSH of sudden onset following trauma, successfully treated with conservative therapy. Aim: This case highlights butterfly vertebrae as an incidental imaging finding before SSH diagnosis. Case study: A 30-year-old female presented with weakness in the lower extremities after trauma, accompanied by paresthesia, urinary retention, and impaired defecating function. The thermoregulatory sweat exam revealed sudomotor dysfunction. Multiple slice computed tomography (MSCT) examination of the whole spine revealed wedge deformity of vertebral corpus (VC) L4 on the right lateral side, and VC L5 butterfly vertebrae. Spine magnetic resonance imaging (MRI) revealed an extramedullary intradural lesion at the T7 to T10 level suggestive of subdural hematoma. Results and discussion: The administration of methylprednisolone pulse therapy, combined with physical rehabilitation, led to a rapid and significant improvement in the patient's motor function. The absence of the spinal pain possibly indicated that there was no more extension of the hematoma; motor recovery, even if slight, should be a predictor of successful conservative therapy, and physical rehabilitation. Conclusions: SSH is an uncommon condition, with varying clinical presentation, and progression. This case report highlights significant improvement following conservative steroid treatment of a SSH. It also highlights a unique incidental finding of butterfly vertebra in a patient with paraparesis following trauma.
- 13 October 2024
- Published by Uniwersytet Warminsko-Mazurski in Polish Annals of Medicine
- Vol. 31 (2) , 1-5
Open AccessSteroid response in a rare case of vertebrae butterfly with spinal cord compression caused by chronic subdural hematoma
Introduction: Spinal subdural hematoma (SSH) is a rare entity. Clinical symptoms include motor, sensory and/or autonomic dysfunction due to compression of the spinal cord. There is no standard consensus in the management of SSH. Here, we report a rare case of SSH of sudden onset following trauma, successfully treated with conservative therapy. Aim: This case highlights butterfly vertebrae as an incidental imaging finding before SSH diagnosis. Case study: A 30-year-old female presented with weakness in the lower extremities after trauma, accompanied by paresthesia, urinary retention, and impaired defecating function. The thermoregulatory sweat exam revealed sudomotor dysfunction. Multiple slice computed tomography (MSCT) examination of the whole spine revealed wedge deformity of vertebral corpus (VC) L4 on the right lateral side, and VC L5 butterfly vertebrae. Spine magnetic resonance imaging (MRI) revealed an extramedullary intradural lesion at the T7 to T10 level suggestive of subdural hematoma. Results and discussion: The administration of methylprednisolone pulse therapy, combined with physical rehabilitation, led to a rapid and significant improvement in the patient's motor function. The absence of the spinal pain possibly indicated that there was no more extension of the hematoma; motor recovery, even if slight, should be a predictor of successful conservative therapy, and physical rehabilitation. Conclusions: SSH is an uncommon condition, with varying clinical presentation, and progression. This case report highlights significant improvement following conservative steroid treatment of a SSH. It also highlights a unique incidental finding of butterfly vertebra in a patient with paraparesis following trauma.
Development of a reverse transcription loop‐mediated isothermal amplification assay with novel quantitative pH biosensor readout method for SARS‐CoV‐2 detection
Reverse transcription loop‐mediated isothermal amplification (RT‐LAMP) is a molecular amplification method that can detect SARS‐CoV‐2 in a shorter time than the current gold‐standard molecular diagnostic reverse transcription‐polymerase chain reaction (RT‐PCR). However, previously developed RT‐LAMP assays have mostly relied on highly subjective visual colorimetric interpretation. In this study, an RT‐LAMP assay was developed with quantitative measurement of reaction pH using a novel portable pH biosensor compared to qualitative colorimetric interpretation and gel electrophoresis, with 57 clinical COVID‐19 samples used for validation of the test. The LoD of the assay is 103 copies/μL. The highest sensitivity was found in the qualitative methods (93.75%), while the highest specificity and likelihood ratio was found in the pH sensor (87.5% and 6.72). On the sensor measurement, a significant difference (p < 0.0001) was observed between the average pH of the RT‐PCR (+) COVID‐19 (6.15 ± 0.27), while the average pH of the RT‐PCR (−) samples (6.72 ± 0.22). Correlation analysis revealed a strong correlation (r = 0.78, p < 0.0001) between the Ct values obtained from RT‐PCR with the biosensor pH readout. RT‐LAMP with the quantitative pH sensor readout method has the potential to be further developed as an objective molecular assay for rapid and simple detection of SARS‐CoV‐2.
Development of a reverse transcription loop‐mediated isothermal amplification assay with novel quantitative pH biosensor readout method for SARS‐CoV‐2 detection
Reverse transcription loop‐mediated isothermal amplification (RT‐LAMP) is a molecular amplification method that can detect SARS‐CoV‐2 in a shorter time than the current gold‐standard molecular diagnostic reverse transcription‐polymerase chain reaction (RT‐PCR). However, previously developed RT‐LAMP assays have mostly relied on highly subjective visual colorimetric interpretation. In this study, an RT‐LAMP assay was developed with quantitative measurement of reaction pH using a novel portable pH biosensor compared to qualitative colorimetric interpretation and gel electrophoresis, with 57 clinical COVID‐19 samples used for validation of the test. The LoD of the assay is 103 copies/μL. The highest sensitivity was found in the qualitative methods (93.75%), while the highest specificity and likelihood ratio was found in the pH sensor (87.5% and 6.72). On the sensor measurement, a significant difference (p < 0.0001) was observed between the average pH of the RT‐PCR (+) COVID‐19 (6.15 ± 0.27), while the average pH of the RT‐PCR (−) samples (6.72 ± 0.22). Correlation analysis revealed a strong correlation (r = 0.78, p < 0.0001) between the Ct values obtained from RT‐PCR with the biosensor pH readout. RT‐LAMP with the quantitative pH sensor readout method has the potential to be further developed as an objective molecular assay for rapid and simple detection of SARS‐CoV‐2.
- 14 March 2023
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 22 (1) , 801-815
A systematic proteomic profiling and pathway analysis of protein biomarkers in diabetic retinopathy with subsequent validation of the IL-6 upstream regulator
Purpose Diabetic retinopathy (DR) is a leading cause of irreversible blindness worldwide. Identifying risk factors associated with DR development and progression is crucial for improving treatment efficacy. Although proteomic changes in DR have been extensively studied, the results remain equivocal. Hence, this study aims to summarize and identify potential diagnostic or prognostic markers for DR. In addition, the upstream regulator responsible for protein deregulation of this disease was also validated. Methods We systematically analyzed the current literature on proteomic profile changes in DR, followed by pathway analysis identification. To validate the protein level changes, ELISA was performed from serum samples collected from 27 patients with DR and 25 healthy controls. Results Our analysis revealed that 1 candidate marker (afamin [AFM]) distinguished non-proliferative diabetic retinopathy (NPDR) from type 2 diabetic patients with no diabetic retinopathy/controls, 65 candidate markers distinguished proliferative diabetic retinopathy (PDR) from NPDR, 1 candidate marker (thyroid receptor-interacting protein 11 [TRIP11]) distinguished PDR from PDR-DME/DME, and 3 candidate markers for therapeutic evaluation of PDR. Our results pinpoint that inflammatory response, which IL-6 mainly modulated, is responsible for the changes of proteomic profiles identified in DR. This was also validated by ELISA analysis, indicating that IL-6 could be potentially useful for diagnosing DR. Conclusion We report a comprehensive patient-based proteomic approach to identify potential biomarkers for DR diagnosis, prognosis, and treatment evaluation.
- 14 March 2023
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 22 (1) , 801-815
A systematic proteomic profiling and pathway analysis of protein biomarkers in diabetic retinopathy with subsequent validation of the IL-6 upstream regulator
Purpose Diabetic retinopathy (DR) is a leading cause of irreversible blindness worldwide. Identifying risk factors associated with DR development and progression is crucial for improving treatment efficacy. Although proteomic changes in DR have been extensively studied, the results remain equivocal. Hence, this study aims to summarize and identify potential diagnostic or prognostic markers for DR. In addition, the upstream regulator responsible for protein deregulation of this disease was also validated. Methods We systematically analyzed the current literature on proteomic profile changes in DR, followed by pathway analysis identification. To validate the protein level changes, ELISA was performed from serum samples collected from 27 patients with DR and 25 healthy controls. Results Our analysis revealed that 1 candidate marker (afamin [AFM]) distinguished non-proliferative diabetic retinopathy (NPDR) from type 2 diabetic patients with no diabetic retinopathy/controls, 65 candidate markers distinguished proliferative diabetic retinopathy (PDR) from NPDR, 1 candidate marker (thyroid receptor-interacting protein 11 [TRIP11]) distinguished PDR from PDR-DME/DME, and 3 candidate markers for therapeutic evaluation of PDR. Our results pinpoint that inflammatory response, which IL-6 mainly modulated, is responsible for the changes of proteomic profiles identified in DR. This was also validated by ELISA analysis, indicating that IL-6 could be potentially useful for diagnosing DR. Conclusion We report a comprehensive patient-based proteomic approach to identify potential biomarkers for DR diagnosis, prognosis, and treatment evaluation.
- 17 October 2022
- Published by Wiley in Clinical Genetics
- Vol. 103 (2) , 146-155
A systematic review on Treacher Collins syndrome: Correlation between molecular genetic findings and clinical severity
Treacher Collins syndrome (TCS, OMIM: 154500) is a rare congenital craniofacial disorder that is caused by variants in the genesTCOF1,POLR1D,POLR1C, andPOLR1B. Studies on the association between phenotypic variability and their relative variants are very limited. This systematic review summarized the 53 literatures from PubMed and Scopus to explore the potential TCS genotype–phenotype correlations with statistical analysis. Studies reporting both complete molecular genetics and clinical data were included. We identified that the molecular anomaly withinTCOF1(88.71%) accounted for most TCS cases. The only true hot spot forTCOF1was detected in exon 24, with recurrent c.4369_4373delAAGAA variant is identified. While the hot spot forPOLR1D,POLR1C, andPOLR1Bwere identified in exons 3, 8, and 15, respectively. Our result suggested that the higher severity level was likely to be observed in Asian patients harboringTCOF1variants rather thanPOLR1. Moreover, common 5‐bp deletions tended to have a higher severity degree in comparison to any variants within exon 24 ofTCOF1. In summary, this report suggested the relationship between genetic and clinical data in TCS. Our findings could be used as a reference for clinical diagnosis and further biological studies.
- 17 October 2022
- Published by Wiley in Clinical Genetics
- Vol. 103 (2) , 146-155
A systematic review on Treacher Collins syndrome: Correlation between molecular genetic findings and clinical severity
Treacher Collins syndrome (TCS, OMIM: 154500) is a rare congenital craniofacial disorder that is caused by variants in the genesTCOF1,POLR1D,POLR1C, andPOLR1B. Studies on the association between phenotypic variability and their relative variants are very limited. This systematic review summarized the 53 literatures from PubMed and Scopus to explore the potential TCS genotype–phenotype correlations with statistical analysis. Studies reporting both complete molecular genetics and clinical data were included. We identified that the molecular anomaly withinTCOF1(88.71%) accounted for most TCS cases. The only true hot spot forTCOF1was detected in exon 24, with recurrent c.4369_4373delAAGAA variant is identified. While the hot spot forPOLR1D,POLR1C, andPOLR1Bwere identified in exons 3, 8, and 15, respectively. Our result suggested that the higher severity level was likely to be observed in Asian patients harboringTCOF1variants rather thanPOLR1. Moreover, common 5‐bp deletions tended to have a higher severity degree in comparison to any variants within exon 24 ofTCOF1. In summary, this report suggested the relationship between genetic and clinical data in TCS. Our findings could be used as a reference for clinical diagnosis and further biological studies.